RxDoctor Payments Data

Niraj Niraula, MD

Pulmonary Disease · Youngstown, OHNPI 1215223722

Payments from drug & device makers

$12,358in general payments, 2019–2025

Across 262 payments — averaging $47.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Noah Medical Corporation$3K
  • Pulmonx Corporation$3K
  • Intuitive Surgical$2K
  • United Therapeutics Corporation$1K
  • Actelion Pharmaceuticals US, Inc.$953
  • GSK$623
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$5,22642%
  • Food & beverage$6,95556%
  • Education$1771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,358 in reported general payments places this provider in the 75th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$100,994
Medicare patients
220
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate15$226,633
AdempasRiociguat11$155,213
Trelegy ElliptaFluticasone/Umeclidin/Vilanter190$145,500
Spiriva RespimatTiotropium Bromide23$15,369
Breo ElliptaFluticasone/Vilanterol21$9,415
Sildenafil Citrate23$5,220
Albuterol Sulfate HfaAlbuterol Sulfate183$4,869
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,401
Ventolin HfaAlbuterol Sulfate33$1,832
Roflumilast14$1,056
Fluticasone Propionate12$272
Pantoprazole Sodium17$240
Montelukast Sodium21$157
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$124
Prednisone47$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$114$242,00238 claims
BayerAdempas$35$155,21311 claims
GSKTrelegy Ellipta, Breo Ellipta$623$154,915211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →